Alterations in triglyceride rich lipoproteins are related to endothelial dysfunction in metabolic syndrome

Clinical Biochemistry

Volumn 49, Issue 12, 2016, Pages 932-935

  Lucero, Diego ^a   López, Graciela I ^a   Gorzalczany, Susana ^a   Duarte, Mariano ^a   González Ballerga, Esteban ^a   Sordá, Juan ^a   Schreier, Laura ^a   Zago, Valeria ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Endothelial dysfunction; Endothelium; Metabolic syndrome; Triglyceride rich lipoprotein

Indexed keywords

ACETYLCHOLINE; GLUCOSE; INSULIN; LIPOPROTEIN; NORADRENALIN; TRIACYLGLYCEROL; TRIGLYCERIDE RICH LIPOPROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LIPID; LIPOPROTEIN TRIGLYCERIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ENDOTHELIAL DYSFUNCTION; HUMAN; IN VITRO STUDY; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; PRIORITY JOURNAL; PULSE WAVE; VASODILATATION; BLOOD; COMPLICATION; FEMALE; FOLLOW UP; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VASCULAR DISEASES; VASCULAR ENDOTHELIUM;

BIOMARKERS; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; RISK FACTORS; TRIGLYCERIDES; VASCULAR DISEASES;

EID: 84969951541     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2016.04.016     Document Type: Article

References (16)

1. [1] Brunzell, J.D., Ayyobi, A.F., Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am. J. Med. 115 (2003), 24S–28S.
2. [2] Rusak, E.J., Bellido, C.A., Iavicoli, O.R., Vazquez, S.T., Duarte, M., Lerman, J., Assessment of endothelial function by means of flow-mediated changes using pulse wave velocity. J. Clin. Hypertens. (Greenwich) 12 (2010), 495–501.
3. [3] Zago, V., Lucero, D., Macri, E.V., Cacciagiú, L., Gamba, C.A., Miksztowicz, V., et al. Circulating very-low-density lipoprotein characteristics resulting from fatty liver in an insulin resistance rat model. Ann. Nutr. Metab. 56 (2010), 198–206.
4. [4] Lucero, D., Zago, V., López, G.H., Cacciagiú, L., López, G.I., Wikinski, R., et al. Predominance of large VLDL particles in metabolic syndrome, detected by size exclusion liquid chromatography. Clin. Biochem. 45:4–5 (2012), 293–297.
5. [5] Alberti, K.G., Eckel, R.H., Grundy, S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120 (2009), 1640–1645.
6. [6] Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis assessment model: insulin and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
7. [7] Bartlett, G.R., Phosphorus assay in column chromatography. J. Biol. Chem. 234 (1959), 466–468.
8. [8] Zago, V., Gorzalczany, S., Lucero, D., Taira, C., Schreier, L., Role of HDL in neutralizing the VLDL effect on endothelial dysfunction. Microvasc. Res. 89 (2013), 153–158.
9. [9] Guide for the Care and Use of Laboratory Animals, National Institutes of Health. Publication No. 85-23, revised 1996.
10. [10] Lteif, A.A., Han, K., Mather, K.J., Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation 112:1 (2005), 32–38.
11. [11] Sukumar, P., Viswambharan, H., Imrie, H., Cubbon, R.M., Yuldasheva, N., Gage, M., Galloway, S., Skromna, A., Kandavelu, P., Santos, C.X., Gatenby, V.K., Smith, J., Beech, D.J., Wheatcroft, S.B., Channon, K.M., Shah, A.M., Kearney, M.T., Nox2 NADPH oxidase has a critical role in insulin resistance-related endothelial cell dysfunction. Diabetes 62:6 (2013), 2130–2134.
12. [12] Tian, J., Wang, J., Li, Y., Villarreal, D., Carhart, R., Dong, Y., Wen, Y., Liu, K., Endothelial function in patients with newly diagnosed type 2 diabetes receiving early intensive insulin therapy. Am. J. Hypertens. 25:12 (2012), 1242–1248.
13. [13] Wang, W., Hein, T.W., Zhang, C., Zawieja, D.C., Liao, J.C., Kuo, L., Oxidized low-density lipoprotein inhibits nitric oxide-mediated coronary arteriolar dilation by up-regulating endothelial arginase I. Microcirculation 18 (2011), 36–45.
14. [14] Lewis, T.V., Dart, A.M., Chin-Dusting, J.P., Non-specific inhibition by human lipoproteins of endothelium dependent relaxation in rat aorta may be attributed to lipoprotein phospholipids. Cardiovasc. Res. 34 (1997), 590–596.
15. [15] Lundman, P., Tornvall, P., Nilsson, L., Pernow, J., A triglyceride-rich fat emulsion and free fatty acids but not very low density lipoproteins impair endotheliumdependent vasorelaxation. Atherosclerosis 159 (2001), 35–41.
16. [16] Adiels, M., Olofsson, S.O., Taskinen, M.R., Borén, J., Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28:7 (2008), 1225–1236.